No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Autophagy is the process by which cells digest and renew their internal structures, recycling damaged or malfunctioning ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

But amid all the fervor and history-making lies a few teething issues. Namely, even with the improved specificity CRISPR-Cas9 has brought to gene-editing, accidental, off-target effects still happen.

CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Africa is grappling with severe food insecurity in the wake of consecutive droughts, climate change, and ongoing conflicts, which are affecting millions across the continent.

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...